3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
1
Phase 1/2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Conditions
Multiple Myeloma
168
Precursor Cell Lymphoblastic Leukemia-Lymphoma
33
Recurrence
28
Leukemia
24
Vomiting
23
Neoplasms, Plasma Cell
20
Lymphoma
18
Neoplasms
16
Nausea
13
Burkitt Lymphoma
11
Prostatic Neoplasms
8
Immunoglobulin Light-chain Amyloidosis
7
Carcinoma, Non-Small-Cell Lung
6
Lymphoma, Follicular
5
Lung Neoplasms
5
Hodgkin Disease
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Lymphoma, Non-Hodgkin
4
Leukemia, Biphenotypic, Acute
4
Breast Neoplasms
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Paraproteinemias
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Fallopian Tube Neoplasms
3
Interventions
pembrolizumab
95
Cisplatin
35
Paclitaxel
27
Carboplatin
27
Docetaxel
17
lenvatinib
15
Fluorouracil
14
Saline Solution
13
Capecitabine
12
Pemetrexed
10
Gemcitabine
10
Oxaliplatin
9
Cetuximab
7
Albumin-Bound Paclitaxel
7
olaparib
6
epacadostat
6
Bevacizumab
6
130-nm albumin-bound paclitaxel
6
Leucovorin
5
enzalutamide
4
Etoposide
4
trifluridine tipiracil drug combination
3
regorafenib
3
belzutifan
3
Prednisone
3
Irinotecan
3
Glucose
3
Dexamethasone
3
liposomal doxorubicin
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Dexamethasone
×
Clear all
NCT03834506
2025-07-18
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Completed
1,030 enrolled
24 charts
NCT04907227
2024-07-12
KEYNOTE-921
Merck Sharp & Dohme LLC
Phase 3
Terminated
81 enrolled
19 charts
NCT03950674
2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3
Completed
40 enrolled
20 charts